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In the 21st century, an array of microbiological and molecular allow antigens for new vaccines to be
specifically identified, designed, produced and delivered with the aim of optimising the induction of a
protective immune response against a well-defined immunogen. New knowledge about the functioning
of the immune system and host pathogen interactions has stimulated the rational design of vaccines. The
design toolbox includes vaccines made from whole pathogens, protein subunits, polysaccharides,
pathogen-like particles, use of viral/bacterial vectors, plus adjuvants and conjugation technology to
increase and broaden the immune response. Processes such as recombinant DNA technology can simplify
the complexity of manufacturing and facilitate consistent production of large quantities of antigen. Any
new vaccine development is greatly enhanced by, and requires integration of information concerning:
1. Pathogen life-cycle & epidemiology. Knowledge of pathogen structure, route of entry, interaction
with cellular receptors, subsequent replication sites and disease-causing mechanisms are all important
to identify antigens suitable for disease prevention. The demographics of infection, specific risk groups
and age-specific infection rates determine which population to immunise, and at what age.
2. Immune control & escape. Interactions between the host and pathogen are explored, with determi-
nation of the relative importance of antibodies, T-cells of different types and innate immunity, immune
escape strategies during infection, and possible immune correlates of protection. This information guides
identification and selection of antigen and the specific immune response required for protection.
3. Antigen selection & vaccine formulation. The selected antigen is formulated to remain suitably
immunogenic and stable over time, induce an immune response that is likely to be protective, plus be
amenable to eventual scale-up to commercial production.
4. Vaccine preclinical & clinical testing. The candidate vaccine must be tested for immunogenicity,
safety and efficacy in preclinical and appropriately designed clinical trials.
This review considers these processes using examples of differing pathogenic challenges, including
human papillomavirus, malaria, and ebola.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Natural immunity against a pathogen derives from the inte-
grated activation of the innate and adaptive immune systems
(Table 1) [1]. Innate immunity arises after detection of specific
pathogen-associated molecular patterns (PAMPs) through a variety
of pattern recognition receptors (PRRs) [2]. The PRRs are able to
detect common structural and functional features associated with
different classes of microorganisms, and depending on the type of
PAMP, activate specialised Antigen Presenting Cells (APCs) e.g.,
dendritic cells. Activation of innate immunity induces expansion
Table 1
Key characteristics and effectors cells of the innate and adaptive immune response.
Innate immunity: first line of defence Adaptive immunity: second line of defence
 Triggered by damage or threat (recognition of PAMPs)  Activated by pathogen encounter
 Rapid response (hours)  Slower response (days or weeks)
 Usually No development of immune memory  Large repertoire of effector molecules
 Pathogen destruction via phagocytosis, killing and release of bioactive mediators  Antibody mediated and T-cell mediated destruction
 Triggers tissue repair  Development of memory
 Stereotypical response  Highly specific and adaptable
 Triggers downstream adaptive responses via antigen-presenting cells
 Effector cells: Granulocytes (basophils, neutrophils, eosinophils),
Mast cells, Macrophages, Monocytes, Natural killer cells, Dendritic cells
 Effector cells: CD4+ T-cells, CD8+ T-cells, B-cells, Plasma cells
PAMPS = pathogen-associated molecular patterns.
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antigen-specific T-cell effector and antibody mechanisms. The
immunological memory derived from this antigen-specific
response persists and can react more rapidly upon subsequent
infection [3].
Immunisation is the strategy of stimulating the host’s defence
against a specific pathogen to establish immunological memory
and thus protect against the consequences of infection. Some vac-
cines are made of whole viruses or bacteria which contain the
microbial elements (PAMPs) that trigger the innate immune
response required to initiate a suitable adaptive response. How-
ever, a whole-pathogen approach may not be feasible, practically
or from a safety perspective, or desirable, especially if the agent
is very reactogenic or tumorogenic. In such cases, partial fraction-
ation may reduce reactogenicity or tumorgenicity by removing
some pathogen components. Alternatively, recombinant DNA tech-
nology and biotechnology, or chemical purification can be used to
produce a subunit of the pathogen as the vaccine antigen. The lat-
ter approaches require in-depth knowledge of the biology of the
pathogen to identify the immunologically-relevant vaccine compo-
nent(s). Since purified proteins usually demonstrate poor immuno-
genicity by themselves, adjuvants are used to enhance and
modulate the immune responses by providing innate/PAMP trig-
gers, thereby driving a protective response to the pathogenic
threat. Combining the correct antigens and adjuvants to optimise
the subsequent downstream adaptive immune response is a cru-
cial task in the development of any new vaccine. Here we discuss
the key principles and challenges faced in the development of vac-
cines targeting a diverse set of pathogens from concept to clinical
trial in humans.2. Pathogen life-cycle and epidemiology
Detailed knowledge of the biology and structure of the patho-
gen, its interaction with cellular receptors and its disease-causing
mechanisms is important in order to identify antigens suitable
for disease prevention. For some microorganisms, characteristics
that differentiate commensal from pathogenic forms may need to
be identified. Where the key subunit immunogens, e.g., capsule
polysaccharides or virus surface proteins, are not conserved, or
broad cross-reactive immunity cannot be generated (e.g., pneumo-
coccus or human papilloma virus [HPV], Box 1 [3–5]), it may be
necessary to prioritise the most common or the most medically
important strains or serogroups. These often vary geographically
or temporally: understanding the epidemiology of the disease is
crucial to identifying the target antigens. The selection of serotypes
is based on complex modelling involving serotype distribution,
value and reimbursement, and the number of different subunits
the vaccine may realistically contain based on costs and complex-
ity of manufacture [6]. Where the epidemiology indicates a con-
strained distribution, a vaccine providing relevant – but less
broad – strain coverage may be preferred on the grounds of costor availability [7]. In some circumstances, such as for seasonal
influenza, variability of the key antigens is unavoidable and a
new vaccine is made each year.
Knowledge of the route of entry and subsequent replication
sites of the pathogen is essential. This is because protection against
pathogens entering via the respiratory (influenza, pneumococcus),
gastrointestinal (Salmonella) or genital tracts (Herpes simplex
virus [HSV] or human immunodeficiency virus [HIV]), or entering
the bloodstream by injury/injection (hepatitis B/C) or mosquito
bite (Malaria, Box 2 [8–10]), may require different vaccination
strategies. To take one example, the immune response after natural
malaria infection is considered to be predominantly directed
against the blood stage of the pathogen but some vaccines have
shown that it is possible to induce effective immunity by targeting
the pre-erythrocytic stage, e.g. during sporozoite stage and the
liver stage of the pathogen [8–10]. Similarly, prevention of the
reactivation of infection may require different strategies to pre-
venting primary infection. Special cases in vulnerable populations
include postpartum infections such as group B streptococcus, and
antenatal/perinatal infection such as hepatitis B (HBV) and HSV,
as well as persistent virus such as Varicella zoster virus (VZV)
and cytomegalovirus (CMV).
The clinical manifestations of the disease of interest and poten-
tial outcomes in the natural setting will also influence the vaccine
requirements. For example, some pathogens, such as pneumococ-
cus, can cause multiple clinical syndromes (invasive disease, pneu-
monia and otitis media), while dengue virus-associated diseases
are substantially more serious when antibodies to one of the four
types are already present [11].
Knowledge of the demographics of infection (poverty, over-
crowding versus delayed exposure in wealthier countries), specific
risk groups and age-specific infection rates determine which pop-
ulation to immunise, and at what age. Having clear diagnostic cri-
teria is fundamental and increasingly these diagnostic approaches
include the capacity to identify both pathogen and serotype. Part-
ner diagnostics are now being developed to support new vaccines.
If the accuracy of diagnosis is poor, then the frequency of infection
may be grossly under- or over-estimated, which has implications
for understanding the disease burden to be prevented, and the
impact of the vaccine after it is used.
The breadth of challenge for successful vaccine development is
illustrated by comparison of the diversity of structure, polymor-
phism, natural history of infection and the consequence for human
health of oncogenic HPV (Box 1), Plasmodium falciparum (responsi-
ble for the most aggressive malaria) (Box 2), and haemorrhagic
Ebolavirus (Box 3 [12–14]).3. Natural immune control & escape
Human pathogens show enormous diversity in their biology,
differing in the type of infection they induce (acute, chronic,
latent), tissue target (skin or mucosal infections of the gastroin-
Box 1
Human papillomavirus (HPV) vaccines.
Pathogen High risk HPV
Disease Anogenital & oral pharyngeal cancer
Structure & diversity  8 kb, double-stranded DNA papillomavirus
 genome encodes 8 proteins
 55 nm particle of 72 capsomeres composed of major L1 & minor L2 capsid proteins
 12 High Risk oncogenic types(16,18, 31,33, 39,45, 51,52, 56,58 & 59)
 70% of cancer caused by HPV types 16, 18
Life cycle & epidemiology  Exclusively epithelial; no viraemia
 Infection of basal epithelia mainly through sexual activity causing minor trauma. Productive infection linked to terminal differenti-
ation of epithelium with particle release from uppermost apoptotic cells
 Risk for cancer from persistent infection leading to viral E6 & E7 driven immortalisation & genetic instability
Disease Burden  Premalignant cancers only apparent through screening
 Cervical cancer most prevalent with 230,000 deaths and >0.5 million new cases/year; mostly in the developing world
Natural Immune control
and escape
 Natural immune control and clearance most likely from T-cell immunity against viral early antigens E2,E6 & E7
 Neutralising antibodies develop against L1 but late after infection and only at low levels in 50% patients
 Insufficient neutralising antibodies in cervico-vaginal secretions and local cellular immunity from lack of antigen-presenting cell
activation/ inhibition of effector pathways leading to persistent infection
Vaccine strategy  Vaccination to induce neutralising antibodies to prevent infection prior to sexual debut in females can impact major disease burden
Antigen selection  Recombinant HPV L1 can form a virus-like particle (VLP) mimicking key antigenic features of HPV types
 L1 only made in terminally differentiated cells so cellular immunity not helpful for clearance of infection
 Unknown if natural infection can necessarily boost a vaccinated individual’s antibody response in a timely fashion to prevent
infection
 Animal studies established potential for antibody-mediated protection
 Need neutralising antibodies at sufficient levels to impact infection sites to maximise levels & longevity for sexual life protection;
which can be optimised by the use of adjuvants
Vaccine formulation  A quadrivalent vaccine containing VLPs of types 6, 11, 16 and 18 produced in yeast with an aluminium hydroxyphosphate sulphate
adjuvant
 A bivalent vaccine containing recombinant baculovirus produced HPV 16 & 18 VLPs with aluminium hydroxide + 3-O-de-acylated-4-
mono-phosphoryl lipid A (MPL) adjuvant (ASO4). MPL is a detoxified form of bacterial lipopolysaccharide which binds to Toll like
receptor-4, a pattern recognition receptor
Immunogenicity  HPV cannot easily be grown in vitro, nor is it cytopathic
 Enzyme-linked immunosorbant assay, Competitive Luminex, pseudo-neutralisation or cervicovaginal murine challenge assays of
immunogenicity available are all surrogates for natural infection since there is no known immune correlate of protection
 Immunisation schedules in volunteers based on 2 or 3 vaccinations for both vaccines gave 100% sero-conversion and antibody levels
many fold higher than natural levels
Clinical Trial Design &
testing
 Aim is to prevent cancer but have to use a surrogate endpoint of high grade cervical intraepithelial neoplasia (CIN2/3) in sexually
active young women
 Both vaccines are safe, give virtually 100% efficacy in protection against the vaccine-targeted types of CIN2/3 in women naïve to the
corresponding type at the time of vaccination in early clinical trials support the use of the preferred vaccination strategy. Follow up
times limited
 Use in adolescents is justified by excellent safety and stronger immune responses
 The bivalent ASO4 adjuvant formulation provides for increased cross-protection against oncogenic non-vaccine types; quadrivalent
vaccine gives effective protection against HPV 6/11 associated with genital warts [3]
Future  Nonavalent Vaccine [4] is quadrivalent vaccine plus 5 other HPV types. Licensed but yet to be shown to be more effective than
quadrivalent or bivalent in protection versus CIN3
 Therapeutic vaccines: for treatment of infections or early cancers by targeting E6 and E7 using a plethora of approaches. Recent DNA
vaccine delivered by electroporation met primary clinical endpoint in CIN3 [5]
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non-mucosal target tissues or organs such as the meninges, blood
stream or liver) and location (intracellular versus extracellular).
Many pathogens also show considerable genetic diversity within
their species or virus type. In most cases, infection is met by a
timely innate and subsequent adaptive immune response
leading to control and elimination of the infection. However,
pathogens often express a number of virulence determinants that
allow the pathogen to avoid immune defences, facilitating infectiv-
ity and transmission. These include stealthy infection, whereby
pathogen-encoded determinants bind to specific cellular receptors
allowing cell entry without alerting the immune response (viruses
and some bacteria), production of proteins, enzymes and micro-
RNAs that inhibit host-pathogen recognition mechanisms and
innate immune effector responses (influenza A) [15], and produc-
tion of structures such as polysaccharide capsules that inhibit
immune effectors such as complement (Neisseria meningitidis)
[16]. Other virulence determinants are structural changes that pro-
mote intracellular sequestration (Escherichia coli) [17], high rates of
mutation that ensure that antibodies stimulated during earlier
infection remain ineffective (influenza, HIV, hepatitis C) [18],
expression of toxins that cause tissue destruction and modulatethe immune response (pneumococcus) [19], mimicry of host pro-
teins (meningococcus serotype B) [20], and latent stages that
remain undetected by the immune system (herpes viruses, HIV,
tuberculosis) [21]. Detailed knowledge of immune escape strate-
gies used by individual pathogens is important for developing
effective vaccines against them.
A major goal in vaccine development is determining the
immune response that must be elicited by vaccination; the so-
called ‘correlate of protection’. Antibody-mediated neutralisation
has traditionally been the major target of vaccines, as many patho-
gens require receptor-mediated binding to cells and/or fusion, or
mediate pathogenicity by producing specific toxins; all of which
can represent protective antibody targets. Newer vaccines target-
ing more complex pathogens are designed to enhance other
aspects of the innate and adaptive response. The relative contribu-
tion of antibodies, CD4+ and CD8+ T-cells and innate immunity to
protection against infection needs to be evaluated and transposed
to vaccine-induced primary immunity or to immunotherapy of
persistent or recurrent infections. The role of selected T-cell-
mediated effector functions, including pro-inflammatory cytokine
production and help for antibody-mediated immunity, also needs
to be determined.
Box 2
Malaria vaccine.
Pathogen Plasmodium falciparum
Disease Malaria
Structure & diversity  23mb Haploid parasite
 Genome encodes 5500 proteins
 P. falciparum is the most virulent (98% mortality; most drug resistant) of 5 species of human parasites. Others have slightly different
life-cycles with geographic and antigenic diversity
Life-cycle & epidemiology  Transmission by female anophelene mosquito; 3 life cycle phases
 Pre-erythrocytic (invasive sporozoites develop to large schizonts in liver)
 Asexual blood stage merozoite invasion & replication in erythrocytes with significant parasitaemia causing clinical symptoms
 Sexual stage: male & female gametocytes in blood ingested by mosquito
Disease Burden  584,000 deaths; 198 million clinical illnesses, majority in sub-Saharan Africa
Natural Immune control
and escape
 Distinct immune control mechanisms at each stage; depending on whether parasite is extra- or intracellular, antibody and/or cellular
immunity can provide protection (unknown% of infections)
 Abundant genetic polymorphism evolved to escape host immune responses
Vaccine strategy  Many different strategies being tested. Most advanced targets the pre-erythrocytic stages of the cycle through P. falciparum circum-
sporozoite protein (CSP) immunity
Antigen selection  CSP present on sporozoite surface, expressed by early liver forms; exported to the cytoplasm of hepatocytes
 CSP conformation has functional properties relating to parasite binding, motility, cell traversal & biochemistry
 Based on experience in development of Hepatitis B (HB) vaccine a fusion construct was made with repetitive immuno-dominant B
cell epitope in central region (R) & T-cell epitope (T) in C-terminal flanking region from CSP genetically fused to HBs Ag (S) &
expressed together with free HBs antigen in yeast. The proteins assemble into VLPs like HBsAg proteins
Vaccine Formulation (e.gs)  RTS,S was tested with different adjuvant formulations with AS01 showing the best immunogenicity and efficacy against controlled
human malarial infection
 ASO1 is a liposomal suspension of the immune enhancers MPL and QS21, a natural saponin molecule
Immunogenicity  Testing in animal models is of limited value
 The vaccine’s mechanism of action is to induce a specific anti-CSP immune response that prevents initiation of blood-stage infection
by killing parasites at the pre-erythrocyte stage. There is no immune correlate of protection
 Anti-CSP antibody & CD4 T-cell activation have been correlated in human subjects
Clinical Trial Design &
testing
 PATH (Program for Appropriate Technology in Health) Malarial Vaccine initiative plus World Health Organization vaccine technology
road map challenge is to license a vaccine that is >50% efficacious for >1 year against severe disease and death
 Focus on reducing the burden of P. falciparum disease in infants & children in sub-Saharan Africa
 Immunogenicity better with 3 dose schedules
 Phase 2 in conditions of natural exposure confirmed vaccine is safe and conferred partial protection
 Phase 3 study in 11 centres across 7 countries with various patterns of malarial transmission shown to prevent a proportion of severe
malaria occurrence in infants and has been submitted for licensure
 Immunisation (3) of children (5–17 months) & infants (6–12 weeks). Vaccine efficacy against clinical malaria (fever & parasitaemia)
at 20 months was 50% or 30% respectively. Lower antibody levels in infants may derive from immaturity of the immune system, pas-
sive transfer of CSP, or HBs co-vaccinations
Future [8–10]  Need for higher efficacy through increased immunogenicity using RTS,S/AS01 alternative immunisation regimes, use of other CSP-
based platforms & combination of RTS,S/AS01 with alternative antigens of pre-erythrocytic, blood or sexual stages
 Whole P. falciparum sporozoite vaccines
 Heterologous prime/boost DNA, rV & or bacteria/rProtein + adjuvant
 Extracellular gamete antigens to prevent transfer to mosquito. Requires herd immunity to reduce infections in community
QS-21: Quillaja saponaria Molina: fraction 21. (Antigenics Inc, a wholly owned subsidiary of Agenus Inc., Lexington, MA, USA).
MPL: 3-deacylated monophosphoryl lipid.
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any given pathogen. For example, antibodies are thought to play a
major role in preventing HBV and influenza infections, whereas T-
cells, especially CD4+ T-cells are believed necessary for control of
tuberculosis. For pathogens such as HIV and influenza virus which
are highly variable, antigenically broad neutralising antibodies
capable of targeting common epitopes are now being explored.
Although non-neutralising antibodies can bind to a virus, they
were thought not to significantly affect virus capacity to infect cells
and replicate. Exceptions are now being identified as antibodies
capable of directing immune killer cells to the pathogen-infected
target have been found to be important [22]. Enhancing antibodies
that result in increased infection have also been reported, so opti-
mising antigen structure is a key aspect of vaccine development.
The uptake and presentation of pathogen-derived antigens to T-
cells by APCs (primarily dendritic cells in the primary immune
response, and monocyte-derived cells and B-cells in subsequent
responses) can be exploited by vaccination [23]. New generation
vaccine adjuvants target these APCs via their PRRs, enhancing their
ability to present antigen, migrate and stimulate T-and B-cell effec-
tor cells [24,25]. These adjuvants can replace and even exceed the
effects of natural pathogen PAMPS (e.g., the adjuvanted Herpes
zoster vaccine [26]). The clinical outcome to be prevented needs
to be defined (systemic infection, mucosal disease, reactivation,severe disease). For many diseases, data on surrogate markers or
correlates of protection may only be attainable after licensure
when the vaccine is used in large populations. Nevertheless,
immunologic studies in clinical trials of partially effective vaccines
are especially important in guiding future improvement of the can-
didate. Such trials could potentially identify crucial mechanisms by
comparing vaccinees with breakthrough infections to those appar-
ently protected.
As examples, the evasion of immunity for oncogenic HPV
derives from stealthy infection and virus production without cell
death plus viral gene modulation blunting antigen presentation
and effector function (Box 1); for P. falciparum there is immense
genetic polymorphism and a requirement for distinct immune
responses at each stage of a very complex life-cycle (Box 2); for
Ebola infection, which can neutralise key innate immune defences
such as interferon, the impact is so devastating in immune-naïve
individuals there is only a low rate of natural immune-mediated
survival, although this may be protective in those who do survive
(Box 3). For HPV, natural immune clearance is primarily due to
cell-mediated immunity whereas for P. falciparum and Ebola the
characterisation of the key components of natural immunity is
incomplete and/or not fully understood. Note that the relative
importance of immune mechanisms may differ for protection from
disease and for clearance of infection.
Box 3
Ebola vaccine.
Pathogen Ebola
Disease Haemorrhagic fever; disseminated intravascular coagulation, multiple organ failure, massive bleeding, shock, death (mortality can reach
60–90%, higher in children, older adults and pregnant women)
Structure & diversity  RNA virus
 19 Kb Genome encoding 7 proteins
 Helical structure covered by lipid membrane in which is embedded the glycoprotein
Life cycle & epidemiology  Spreads within endemic areas via infected body fluids from bats to non-human primates
 Humans initially acquire infections from these reservoirs in endemic areas in Africa
 Human to human spread via infected body fluids (blood, faeces, saliva, vomit, tears, breast milk, semen)
 Isolated from these fluids up to 40 days after onset, incubation period 5–9 days
 Progressive strain variation as it spreads
 Nosocomial spread via reuse of non-sterile injections, healthcare workers at risk
 Occasional imported infections into western countries
Disease Burden  Only 2600 cases in central Africa up until 2014–15 outbreak of 28,000 cases in Liberia, Guinea and Sierra Leone. Occasional imported
cases create great public anxiety requiring considerable health resources to manage
Natural Immune control
and escape
 Neutralising antibody is critical
 Immune evasion: lymphocyte apoptosis and inhibition of interferon induction
 Endothelial damage and activation by EBOV envelope protein leading to disseminated intravascular coagulation
 Immunopathology: massive pro-inflammatory cytokine release (‘storm’)
Vaccine strategy  Induce neutralising antibodies
 Role of T-cells unclear
Antigen selection  The surface glycoprotein is the target for neutralising antibody & monoclonal antibodies against it (ZMAPP) can prevent & facilitate
cure of infection in non-human primates
Vaccine Formulation (e.gs)  More than 10 vaccine candidates under development: two hybrid recombinant viruses incorporating EBOV immunogenic glycopro-
tein are most advanced: chimp adenovirus 3 (cAd3) –EBO Z(NIH-GSK), recombinant vesicular stomatitis virus (rVSV)-ZEBOV (Cana-
dian Dept. Public Health-Merck)
Immunogenicity  Both advanced vaccine candidates are immunogenic in inducing suprathreshold levels of antibodies in on human primate models
(which were used initially to determine correlates of protection) with a single injection. Vaccines induce lower levels of T-cell
immunity
Clinical Trial Design &
testing
 Phase I trials in Europe and Africa, Phase II–III trials underway in Africa. In African trials, rVSV-ZEBOV showed 75% efficacy in ring
vaccination the closing stages of the large 2014–15 epidemic. However high reactogenicity may preclude general prophylactic
immunisation
 Safety trials planned: 10,000 subjects each for the GSK and Merck vaccines and a placebo
Future  Await phase III results with cAd3-EBOZ and trials with several other candidates which are in development [12,13]. Problem is the
difficulty in testing in humans in view of erratic epidemics [14]. Role of T-cells needs to be clarified
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Classically, ‘protective’ antibodies elicited by natural infection
are studied to identify the main target(s) of the effective immune
response, usually proteins (toxins [such as diphtheria and tetanus
or filamentous haemagglutinin in pertussis vaccines]) or carbohy-
drates (capsular polysaccharides [pneumococcus, meningococ-
cus]). Potential candidates are analysed for suitability as vaccine
antigens, including determining their homology with human pro-
teins and potential inherent toxicity. Detoxification may be
required before an antigen (for example, pertussis toxin) can safely
be administered to humans, but some detoxification methods may
destroy epitopes in the process, and impact immunogenicity [27].
Furthermore, purification of antigens away from other viral and
bacterial components such as lipids and nucleic acids may exclude
PAMPS, altering the nature of the immune response. Initial in vitro
studies may evaluate antigen-antibody binding capacity and func-
tion, and early investigation of the immune response to the candi-
date antigen may be assessed in animals.
However, immunity is not always mediated via a humoral
response (e.g., malaria [Box 2] or tuberculosis); rapid evolution of
the pathogen may mean that potential antigens change rapidly
(influenza and HIV); the antigen may be similar to human proteins,
potentially increasing the risk of autoimmunity (meningococcal
serogroup B capsule, group A streptococcal capsule); a complex
life-cycle may mean that the host is exposed to different antigens
at different times in the life-cycle (malaria, Box 2), or that re-
activation occurs in a previously infected host (VZV, [28]. New
technologies, such as reverse vaccinology [6], are required to iden-
tify candidate antigens for these challenges where the expression
of surface structures is predicted, based on inferred protein
sequences from the pathogen’s genome.Vaccines need to be efficiently produced and deliverable in a
form acceptable to the recipient. The earliest vaccines used whole
organisms; either alive (attenuated versions of the pathogen, or
related but less virulent organisms that could induce cross-
reactive immunity without inducing disease), or dead. Whole
organisms have the advantage of being highly immunogenic and
typically stimulate a response similar to that generated by natural
infection. Unfortunately, they may also generate pathology similar
to that induced by the natural infection; and in cases where natural
infection does not generate protective immunity, a whole-
organism vaccine may be likewise ineffective. There is the sec-
ondary limitation that whole organisms are complex mixtures of
proteins, lipids and carbohydrates, which greatly complicates pro-
duction, characterisation and quality control of the final vaccine.
For these reasons, the focus has shifted toward vaccines con-
taining specific antigens, which can be characterised at the molec-
ular level. The properties of the most commonly-used vaccine
technologies are shown in Table 2. With the exception of whole
organisms, all of these technologies rely on presenting selected,
key antigens that will ensure a strong, persistent and broad
immune response of the kind needed for protection, while avoiding
or minimising reactogenicity. Purified antigens can sometimes be
poorly immunogenic, so the first task is to choose a vaccine deliv-
ery system that boosts immunogenicity and promotes a protective
immune response. It is also essential that the technology selected
is economically viable. Since prophylactic vaccines are typically
administered to very large numbers of healthy individuals they
are among the most price-sensitive of all medical products, and
the acceptable price depends greatly on the target population: a
vaccine for childhood malaria, most needed in some of the poorest
countries in the world, faces different design constraints than one
against, for example, zoster, which is targeted primarily toward
Table 2
Toolbox of technologies currently being used or investigated in vaccine design.
Technology Examples Advantages Disadvantages Limitations
Whole pathogen:
live attenuated
 Oral poliovirus,
 measles-mumps-rubella,
 varicella,
 influenza,
 BCG (Bacillus Calmette-
Guérin)
 Mimics natural infection,
 effective priming with durable immunity
 Rarely may revert to virulence,
 not suitable for some populations (pregnant women,
immunocompromised),
 may induce mild disease symptoms,
 can be difficult to produce consistently
Not suitable for micro-organisms that
do not grow well in culture, or whose
characteristics change throughout
their life-cycle (parasites) or
pathogens with effective immune-
evasion or latent stages
Whole pathogen:
killed
 Inactivated poliovirus,
 hepatitis A,
 whole-cell pertussis
 Induces broad immune response to multiple antigens  Multiple doses needed,
 Reactogenic,
 key epitopes maybe destroyed by the inactivation
process
Related non-
pathogens
 Cowpox (small pox)  Induces broad immune response to multiple antigens  Not suitable for some populations (pregnant women,
immunocompromised),
 may induce mild disease symptoms
Not many micro-organisms are
suitable
Purified protein
(split or
subunit)
 Acellular pertussis vaccines
 influenza
 Induces a highly specific response,
 non-infectious,
 low reactogenicity,
 synthetic production may ease production
 Correct 3-dimensional structure may be difficult to
achieve,
 multiple subunits are often necessary,
 little cross-reactivity,
 potential for escape mutants,
 lower immunogenicity requiring adjuvants
Not suitable for pathogens with
characteristics that change
throughout their life-cycle (parasites,
some chronic or latent infections)
Polysaccharide–
protein
conjugates
 Neisseria meningitidis,
 Streptococcus pneumoniae,
 Haemophilus influenzae
type b
 Conjugation triggers T-cell dependant mechanisms and
immune memory
 Technically difficult and costly to produce
 finite number of strains possible in one vaccine
Pathogen-like
particles
 Malaria,
 hepatitis B,
 human papilloma virus
 Can induce enhanced responses compared to natural
immunity
RNA replicon  Influenza  Unable to produce infection
 suitable for pathogens that do not grow in culture
 Antigen dissemination may be limited
 potential for recombination to infectious form
Recombinant DNA
technology
 Hepatitis B,
 human papilloma virus, her-
pes zoster
 Suitable for pathogens that do not grow well in culture,
 efficient to manufacture
 Lower immunogenicity requiring adjuvants or multiple
peptides
Viral/bacterial
vectors
 Respiratory syncytial virus,
 ebola
 Suitable for pathogens that do not grow well in culture  Pre-existing antibody may limit response,
 different vaccines may be needed for priming and
boosting
Potentially unsuitable for
immunocompromised or pregnant
women
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A.L. Cunningham et al. / Vaccine 34 (2016) 6655–6664 6661adults in developed countries who have the resources to purchase
it. For these reasons, some delivery modalities (for example,
requiring multiple doses, many different components, or separate
vaccine technologies for priming and boosting) may theoretically
improve outcome but prove to be too complex or expensive to
be practical. Formulation becomes key here. Combination vaccines
that target several diseases in a single injection may alleviate cost
and delivery restrictions, but their complexity imposes a higher
development cost and there is the risk of immune interference in
which a component of a combination vaccine may prove less effec-
tive than when tested in isolation. Likewise, the behaviour of an
antigen with different delivery systems is not always predictable,
leading to altered antigen availability dose response or epitope
recognition [29,30]. In the absence of predictive models for these
interactions, there is currently no alternative to time-consuming
(and expensive) in vivo testing.
Alum, the oldest adjuvant (aluminium hydroxide or aluminium
phosphate) has been in use for over 90 years. While alum has
demonstrated an excellent safety record [31], it has been assessed
primarily on its ability to promote humoral immune responses,
with little or no attention paid to the cellular immunity induced
[32]. Early emulsions, such as Freund’s complete adjuvant,
generated highly effective cellular immune responses; but also
unacceptable side effects [33].
When molecular mechanisms involved in the induction
of the immune response to adjuvants were studied and understood
in the 1990s, it was realised that immunogenicity and
immunopathology were promoted by different, partially overlap-
ping immune pathways. This allowed for the development of
new adjuvants that combined enhanced immunogenicity with
acceptable reactogenicity. Several of these are now used in prod-
ucts that are licensed [34,35] and typically include multiple com-
ponents to stimulate a broad range of immune responses
(Table 3 [32,36–40]).
Concurrent with the development of better adjuvants for vac-
cine delivery, other vehicles that allow the tight association of anti-
gen and immunomodulators have been developed. These include,
but are not limited to, toxoids, virosomes, liposomes, immunostim-
ulating complexes (ISCOMS) and micro- or nano-particles. The first
two are already used in commercially-available vaccines (Table 3),
while the rest have provided promising clinical data (reviewed in
[41]). Toxoid-conjugated vaccines, though employing different
technologies to those discussed above, utilise the same generalTable 3
Adjuvants used in currently licensed or approved vaccines.
Adjuvant Composition Mechanism of action
Alum Aluminium hydroxide or
aluminium phosphate
Possible depot effect, directs toward
production [32]
AS01 QS-21 and MPL with liposomes Induction of a broad population of ac
between QS21 and MPL that acts to e
AS03 Oil-in-water emulsion with
alpha-tocopherol (Vitamin E)
Transient NF-jB, cytokine and chemo
innate immune cells. Enhanced recru
draining lymph node. Enhancement o
AS04 MPL adsorbed onto aluminium
hydroxide or aluminium
phosphate
Transient NF-jB, cytokine and chemo
efficiency of activated dendritic cells
MF59 Oil-in-water emulsion with
squalene
Enhances antigen uptake by APCs, cy
the local immune response, increased
response [36]
Virosomes Phospholipids: lecithin, cephalin The virosome structure functions to
mononuclear cells toward a Th1 cyto
QS-21: Quillaja saponaria Molina: fraction 21. (Antigenics Inc, a wholly owned subsidia
MPL: 3-deacylated monophosphoryl lipid.
CpG7909: an immunostimulatory nucleotide.
DTaP – combined diphtheria-tetanus acellular pertussis vaccineconcept; the combination of a detoxified, but immunogenic micro-
bial PAMP able to stimulate innate and T-cell dependent responses,
linked to antigenic polysaccharide targets, which can generate
strong B-cell responses and antibody production. This approach
has been used to generate licenced vaccines against serious inva-
sive bacterial infections (Haemophilus influenzae type b, N. meningi-
tidis, Streptococcus pneumoniae) using toxoids derived from either
tetanospasmin of Clostridium tetani or the diphtheria toxin of
Corynebacterium diphtheria, which have been shown to generate
more robust and long-lived antibody responses than the polysac-
charide targets alone, presumably due to the activation of T-cell
help [42]. Other conjugate vaccines, such as a typhoid vaccine
using a modified exoprotein A from Pseudomonas aeruginosa as
the toxoid are under development [43].
Virosomes, liposomes and ISCOMS, although different in struc-
ture and immunostimulatory capacity, are built around the con-
cept of a lipid vesicle (the lipids used are themselves weakly
immunostimulatory) to which can be added both antigenic targets
and immunomodulatory molecules [37]. The physical properties
and size of the vesicle can be tailored to requirements depending
on the lipid composition and production methods, as can the ionic
charge. These factors influence the ability of the delivery system to
form depots, bind to antigen-presenting cells and the antigen load-
ing of the delivery system [37]. In many ways, these adjuvants
mimic natural enveloped bacteria or viruses, with a lipid envelope
and associated proteins. This process is taken a step further by
virus-like particles (VLP), where the lipids and antigenic target
are derived directly from the pathogen in question, producing a
delivery vehicle that resembles a pathogen but without the genes
required to initiate infection [44].
5. Vaccine preclinical & clinical testing
One of the most challenging aspects of vaccine design remains
assessing the efficacy or effectiveness of new vaccine formulations.
The clinical assessment of vaccines is discussed in more detail in
[58]. In some cases, where clear correlates of immunity can be
observed (such as for measles, where the link between antibody
level and clinical outcome is indisputable [45]), or animal models
which accurately mimic human disease, non-clinical estimates of
efficacy can be made with a high degree of certainty: unfortu-
nately, while having an immune correlate is desirable, and extre-
mely helpful, they are mostly lacking in the early phases ofCurrent use
a Th2-like response with increased antibody Multiple vaccines, including
DTaP, Influenza, etc.
tivated antigen presenting cells, with synergy
nhance the adaptive response [39]
Malaria vaccine, zoster vaccine
kine response, increased recruitment of
itment of innate immune cells at the local
f T-cell mediated help of B-cell responses [40]
Influenza (pre-pandemic and
pandemic)
kine response, increased numbers and
leading to enhanced antibody responses [38]
Human papillomavirus vaccine
hepatitis B (pre- and
haemodialysis patients)
tokine and chemokine response enhancing
quantity and diversity of the antibody
Influenza (seasonal and
pandemic)
enhance update by APCs. Stimulates
kine profile [37]
Influenza, hepatitis A
ry of Agenus Inc., Lexington, MA, USA).
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(induced either by vaccination or natural infection) is generally
observed in protected individuals, it is often difficult to identify
the precise immune mechanism(s) responsible for efficient protec-
tion from the large array of elicited effectors (antibodies, cytokines,
T-cells and so on). As an example, the effectiveness of HBV vaccines
is measured by the ability to induce an antibody response against
the HBV surface antigen (HBsAg) ofP10 mIU/ml of blood) [45,47]
based on the observation that individuals with such a response
were protected from infection. Long-term follow-up indicated that
in some individuals antibody levels waned with time; but these
individuals remained protected from infection [48]. Booster vacci-
nations revealed that vaccinated individuals displaying low to
undetectable levels of serum antibodies were nevertheless able
to mount a robust recall response, indicative of a persistent and
protective immune memory despite a waning humoral response
[49]. The presence of an antibody response after vaccination (or
infection) demonstrates that an immune response has been gener-
ated, but in this case, there is no direct correlation between the
magnitude of the antibody response and the degree of protection.
In other words, antibody production in response to vaccination is
an indicator of immunogenicity, not efficacy. This may be due to
the fine specificity of the protective antibody response, not the
total level of antibody produced. Nonetheless, long experience
with vaccines such as those against pneumococcus and influenza,
has proved that the linkage between immunogenicity and vaccine
effect is so robust, that for these vaccines, generation of a suffi-
ciently strong and mature antibody response is accepted for licen-
sure, even if the antibody is only part of the protective immune
response [50].
The ultimate test of vaccine efficacy is of course, protection in
humans; but when choosing which vaccine candidates to take into
clinical trials, other surrogate approaches are needed. The critical
points along the preclinical pathway include detailing the host-
pathogen interaction, understanding the protective immune
mechanisms involved and selecting an appropriate antigen and
adjuvant to achieve the desired immune response. Subsequent
steps involve the production of the antigen, and a compatible vac-
cine delivery system, followed by the development of immune
readouts and toxicological tests to assess the safety and perfor-
mance of the candidate vaccine construct under preclinical
evaluation.
If a plausible mechanism of protection or suitable surrogate
markers can be identified, animal models can be informative with
regard to protective effects and antigen recognition, even if they do
not replicate the human disease closely enough to be predictive
[51]. Non-human primate and rodent models of Ebola infection
exist, and since efficacy studies are not feasible in view of the spo-
radic nature of Ebola outbreaks, evidence gained from animal mod-
els has been considered to support vaccine licensure [14]. By
contrast, no good animal model for HIV infection has been identi-
fied, though infection of non-human primates with simian immun-
odeficiency virus is a useful surrogate model. However,
improvements to this model and the development of a more
affordable animal model remains a priority [52]. Animal models
have also proven their value for the assessment of vaccine safety
and toxicology, even though preclinical toxicology studies are typ-
ically relatively small, and powered to identify direct toxic effects
[53]. In cases where an effective treatment is available for the dis-
ease, human challenge studies where volunteers agree to be
exposed after vaccination is the closest possible model to human
disease: this approach has been successfully used in malaria vac-
cine development (Box 2), and is being explored for other diseases
that lack suitable animal models such as typhoid fever [54].
Some approaches used for vaccine design and testing are pre-
sented in the examples provided in Boxes 1–3.5.1. HPV vaccines
The licensed HPV vaccines are based on VLP technology [44]
plus an adjuvant, to generate a stronger antibody response than
natural infection. The quadrivalent vaccine uses alum and in the
bivalent HPV vaccine, this is further supplemented by the use of
detoxified monophosphoryl lipid A (MPL), a modified membrane
component common in Gram-negative bacteria, which binds to
TLR4 and stimulates strong cell-mediated immunity [35,55]. The
combination of MPL and aluminium induces higher antibody levels
than aluminium alone [38]. The value of more complex adjuvants
can be seen in direct comparisons of the antibody induced by
alum-adjuvanted antigens and the combination delivery system
and may explain the broad cross-reactivity seen with this vaccine,
and its ability to provide protective immune memory significantly
superior to that derived from natural infection [24,25,56]. Consis-
tent with this, HPV vaccines’ immunogenicity and capacity to
induce long lasting responses were initially tested in HPV-naïve
young women, in which antibody levels were found to exceed
those produced by individuals naturally exposed to HPV. Subse-
quent clinical trials in HPV-naïve young women used a surrogate
endpoint of cancer, high grade cervical intra-epithelial neoplasia
(CIN3), to establish efficacy but as yet there is no immune correlate
of protection with antibody levels. Additionally, the principle vac-
cination target group for prevention of cervical cancer is young
girls before sexual debut, and thus licencing depended on bridging
studies showing greater immunogenicity in this cohort.
Even when there are licenced vaccines against a pathogenic
threat, there is almost always room for improvement. Thus HPV
VLP vaccines containing more oncogenic types, or even therapeutic
vaccines based on HPV oncogenes, which could also be prophylac-
tic, are strategies driving future developments (Box 1).
5.2. Malaria vaccines
The first vaccine against P. falciparum to successfully complete
phase III trials (RTS,S) combines a fusion construct of epitopes from
the Circumsporozoite Protein with HBsAg adjuvanted with AS01, a
liposomal suspension of the immune enhancers MPL and QS21
(Box 2). The malarial vaccine RTS,S may be licenced based on the
available protection data, but there will be a need to further
improve the longevity of the immune response and vaccine impact
to encourage widespread vaccination: for example, while the vac-
cine offers some protection from malaria caused by P. falciparum, a
vaccine against P. vivax, the second most important cause of malar-
ia, is also of high priority [57].
5.3. Herpes zoster vaccine
For herpes zoster, two vaccine strategies have been shown to
stimulate waning cell mediated immunity to earlier infection by
the VZV: high dose whole attenuated virus and a subunit adju-
vanted vaccine which aims to enhance cell-mediated immunity
(Supplementary Box 1). The high efficacy in older people of the
subunit VZV/adjuvant vaccine compared with the results from
independent trials with the highly concentrated attenuated viral
vaccine is very encouraging for overcoming age-related declines
in immune responses [26].
5.4. Dengue vaccines
There are several candidate dengue virus vaccines in various
stages of testing (Supplementary Box 2). A chimeric viral vaccine
using yellow fever as a backbone has been licenced in some coun-
tries and induces neutralising antibodies to all four serotypes, but
optimal use appears to require priming with yellow fever vaccine
A.L. Cunningham et al. / Vaccine 34 (2016) 6655–6664 6663one year previously. For dengue virus vaccines adopting a goal of
preventing hospitalisation rather than complete prevention of dis-
ease may influence future developments [11].
5.5. Ebola vaccines
For Ebola there are more than 10 candidate vaccines under
development. The most advanced are recombinant adeno- and
vesicular-stomatitis virus (VSV) encoding EBOV glycoprotein.
Ebola vaccination strategies based on available hybrid recombi-
nant viruses have been catapulted into clinical testing, driven by
the impact of the recent devastating Ebola outbreak in several Afri-
can countries. The rVSV–ZEBOV vaccine induces elevated levels of
antibodies in primate models and vaccination trials in Africa show
75% efficacy but with high reactogenicity (Box 3). There are many
challenges for comprehensive testing of Ebola vaccines in view of
the epidemic nature of the disease. The wider consequences of
viral persistence after apparent recovery are not yet fully under-
stood and the analysis of the role of cellular immunity in recovery
may be critical to future vaccine design.
6. Conclusion
Vaccine development is a complex multidisciplinary activity,
combining understanding of host-pathogen interactions at the
molecular level, with clinical science, population-level epidemiol-
ogy and the biomechanical requirements of production. The basis
is an understanding of which immune processes shape disease
and protection, and how these vary between individuals, risk
groups and populations. That knowledge in turn informs the selec-
tion of antigenic targets, and the adjuvants/delivery systems used
to shape the immune response induced by the vaccine; which in
turn determines the manufacturing requirements and the clinical
trial design. The ultimate goal is an affordable vaccine that gener-
ates strong and lasting immunity with the fewest possible side
effects, implemented without the need for expensive cold chains.
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